Last reviewed · How we verify
ADZENYS XR-ODT
At a glance
| Generic name | ADZENYS XR-ODT |
|---|---|
| Sponsor | Aytu BioPharma, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- tTIS Targeted of the Striatum as an Intervention for MUD Patients (NA)
- The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine (PHASE4)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users (PHASE2)
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (PHASE2, PHASE3)
- Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR (NA)
- Vyvanse in Children Aged 6 to 12 Years (EARLY_PHASE1)
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADZENYS XR-ODT CI brief — competitive landscape report
- ADZENYS XR-ODT updates RSS · CI watch RSS
- Aytu BioPharma, Inc. portfolio CI